|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
50,230,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Icosavax is a biopharmaceutical company utilizing its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Co.'s pipeline includes vaccine candidates targeting some of viral causes of pneumonia. Co.'s vaccine candidate IVX-A12 is a bivalent candidate, or a mixture of different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus, and IVX-241, a vaccine candidate designed to target human metapneumovirus. Co. is developing additional vaccine candidates to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
225,965 |
272,386 |
481,304 |
| Total Sell Value |
$0 |
$3,496,502 |
$3,919,051 |
$6,446,684 |
| Total People Sold |
0 |
4 |
5 |
7 |
| Total Sell Transactions |
0 |
8 |
14 |
44 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shah Rajeev M. |
Director |
– • • |
2022-03-28 |
4 |
B |
$4.53 |
$794,611 |
I/I |
175,318 |
5,953,665 |
2.25 |
- |
|
| Simpson Adam K. |
Chief Executive Officer |
• • – |
2022-03-28 |
4 |
OE |
$0.84 |
$4,023 |
D/D |
4,789 |
220,482 |
|
- |
|
| Cearley Cassia |
Chief Business Officer |
• – – |
2022-03-18 |
4 |
OE |
$0.84 |
$29,515 |
D/D |
35,137 |
133,550 |
|
- |
|
| Cearley Cassia |
Chief Business Officer |
• – – |
2022-03-07 |
4 |
AS |
$17.13 |
$171,629 |
D/D |
(10,000) |
98,413 |
|
- |
|
| Holtzman Douglas |
Chief Scientific Officer |
• – – |
2022-02-18 |
4 |
GD |
$0.00 |
$0 |
I/I |
20,000 |
22,440 |
|
- |
|
| Richardson Charles E |
SVP, Technical Operations |
• – – |
2022-02-14 |
4 |
OE |
$0.84 |
$62,188 |
D/D |
72,561 |
167,386 |
|
- |
|
| Richardson Charles E |
SVP, Technical Operations |
• – – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
15,942 |
94,825 |
|
- |
|
| Russo Thomas Joseph |
Chief Financial Officer |
• – – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
17,714 |
51,880 |
|
- |
|
| Simpson Adam K. |
Chief Executive Officer |
• • – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
75,578 |
291,271 |
|
- |
|
| Holtzman Douglas |
Chief Scientific Officer |
• – – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
19,485 |
303,633 |
|
- |
|
| Kanesa-Thasan Niranjan |
Chief Medical Officer |
• – – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
19,485 |
242,559 |
|
- |
|
| Cearley Cassia |
Chief Business Officer |
• – – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
21,256 |
108,413 |
|
- |
|
| Bekiroglu Elizabeth |
General Counsel & Corp. Sec. |
• – – |
2022-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
82,992 |
110,742 |
|
- |
|
| Kanesa-Thasan Niranjan |
Chief Medical Officer |
• – – |
2022-02-02 |
4 |
OE |
$0.84 |
$52,101 |
D/D |
52,752 |
221,408 |
|
- |
|
| Simpson Adam K. |
Chief Executive Officer |
• • – |
2022-01-26 |
4 |
OE |
$0.84 |
$90,968 |
D/D |
90,693 |
215,693 |
|
- |
|
| Shiver John W. |
Director |
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
8,500 |
8,500 |
|
- |
|
| Holtzman Douglas |
Chief Scientific Officer |
• – – |
2021-12-31 |
4 |
GD |
$0.00 |
$0 |
I/I |
10,000 |
42,440 |
|
- |
|
| Simpson Adam K. |
Chief Executive Officer |
• • – |
2021-12-21 |
4 |
GA |
$0.00 |
$0 |
I/I |
250,000 |
129,032 |
|
- |
|
| Simpson Adam K. |
Chief Executive Officer |
• • – |
2021-12-21 |
4 |
GD |
$0.00 |
$0 |
I/I |
250,000 |
531,576 |
|
- |
|
| Cearley Cassia |
Chief Business Officer |
• – – |
2021-11-15 |
4 |
OE |
$0.83 |
$18,756 |
D/D |
22,598 |
85,491 |
|
- |
|
| Bekiroglu Elizabeth |
See RemarksOfficer |
• – – |
2021-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,750 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2021-08-02 |
4 |
B |
$15.00 |
$39,999,990 |
I/I |
2,666,666 |
638,668 |
2.25 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,112,681 |
466,902 |
|
- |
|
| Cormorant Private Healthcare Fund Iii Lp |
Former 10% Owner |
– – – |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
I/I |
426,393 |
426,393 |
|
- |
|
| Nicholson Jonathan |
Former 10% Owner |
– – – |
2021-08-02 |
4 |
B |
$15.00 |
$2,000,010 |
D/D |
133,334 |
2,883,329 |
2.44 |
- |
|
119 Records found
|
|
Page 4 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
